Nucleic acid therapeutics for ALS
2024

Rethinking Antisense Oligonucleotide Therapies for ALS

Sample size: 108 publication 10 minutes Evidence: moderate

Author Information

Author(s): D. Ito, K. Okada

Primary Institution: Keio University School of Medicine

Hypothesis

Can antisense oligonucleotides effectively treat amyotrophic lateral sclerosis (ALS)?

Conclusion

Antisense oligonucleotides have shown proof of mechanism by reducing target proteins but have not consistently demonstrated clinical benefits in ALS patients.

Supporting Evidence

  • Tofersen reduced SOD1 protein levels in cerebrospinal fluid but did not improve clinical outcomes.
  • Clinical trials for other antisense oligonucleotides targeting different genes have also shown no significant clinical benefits.
  • Real-world evidence suggests a reduction in neurofilament light chain levels with tofersen treatment.

Takeaway

Scientists are trying to use special drugs called antisense oligonucleotides to help people with ALS, but so far, they haven't made people feel better even though they can lower some harmful proteins.

Methodology

This review discusses various clinical trials and outcomes of antisense oligonucleotide therapies for ALS.

Potential Biases

Potential biases may arise from the limited number of participants and the nature of the trials conducted.

Limitations

The clinical benefits of antisense oligonucleotides in ALS have not been definitively proven despite reductions in target proteins.

Participant Demographics

Participants included individuals with SOD1 mutations and other genetic backgrounds related to ALS.

Statistical Information

P-Value

0.97

Confidence Interval

95% CI, 0.4–6.7

Statistical Significance

p=0.97

Digital Object Identifier (DOI)

10.1002/acn3.52234

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication